Publications by authors named "David C Fry"

Claim this Profile
C
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, David C Fry

Med J Aust· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development.
Binh T Vu, Romyr Dominique, Bruce J Fahr, Hongju H Li, David C Fry

ACS Med Chem Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting protein-protein interactions for drug discovery.
David C Fry

Methods Mol Biol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.
Zhisen Zhang, Zhaohu Lin, Zheng Zhou, Hong C Shen, S Frank Yan, David C Fry

ACS Med Chem Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.
David C Fry, Charles Wartchow, Bradford Graves, Cheryl Janson, Christine Lukacs

ACS Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner.
David C Fry

Curr Pharm Des· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Druggability assessment of protein-protein interfaces.
Jutta Wanner, David C Fry, Zhengwei Peng, John Roberts

Future Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
David C Fry, Bradford Graves, Lyubomir T Vassilev

Methods Enzymol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein-protein interactions as targets for small molecule drug discovery.
David C Fry

Biopolymers· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting protein-protein interactions for cancer therapy.
David C Fry, Lyubomir T Vassilev

J Mol Med (Berl)· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1H, 15N, and 13C resonance assignments of human interleukin-2.
David C Fry, S Donald Emerson, Chao-Min Liu, Robert Palermo

J Biomol NMR· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NMR structure of a complex between MDM2 and a small molecule inhibitor.
David C Fry, S Donald Emerson, Stefan Palme, Binh T Vu, Chao-Min Liu

J Biomol NMR· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides.
Hongmao Sun, David N Greeley, Xin-Jie Chu, Adrian Cheung, Waleed Danho, David C Fry

Bioorg Med Chem· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction.
S Donald Emerson, Robert Palermo, Chao-Min Liu, Jefferson W Tilley, Li Chen, David C Fry

Protein Sci· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis